[1] Zhao R, Shi WZ, Wei EQ, et al. Montelukast, a cysteinyl leukotriene receptor-1 antagonist, attenuates chronic brain injury after focal cerebral ischaemia in mice and rats[J].J Pharm Pharmacol,2011, 63(4):550-557. [2] Wang L, Du C, Lv J, et al. Antiasthmatic drugs targeting the cysteinyl leukotriene receptor 1 alleviate central nervous system inflammatory cell infiltration and pathogenesis of experimental autoimmune encephalomyelitis[J]. J Immunol, 2011,187(5):2336-2345. [3] Lai JE, Hu M, Wang H, et al. Montelukast targeting the cysteinyl leukotriene receptor1 ameliorates Aβ1-42-induced memory impairment and neuroin ammatory and apoptotic responses in mice [J]. Neuropharmacology, 2014, 79:707-714. [4] Tang SS, Hong H, Chen L, et al.Involvement of cysteinyl leukotriene receptor 1 in Aβ1-42-induced neurotoxicity in vitro and in vivo[J]. Neurobiol Aging, 2014, 35(3):590-599. [5] Corbett A, Pickett J, Burns A, et al. Drug repositioning for Alzheimer's disease[J].Nat Rev Drug Discov, 2012,11(11):833-846. [6] Herrmann N, Chau SA, Kircanski I, et al. Current and emerging drug treatment options for Alzheimer's disease: a systematic review [J]. Drugs, 2011,71(15):2031-2065. [7] Mufson EJ, Counts SE, Perez SE, et al. Cholinergic system during the progression of Alzheimer's disease: therapeutic implications[J]. Expert Rev Neurother, 2008,8(11):1703-1718. [8] Desmarais JE, Gauthier S. Alzheimer disease: clinical use of cholinergic drugs in Alzheimer disease[J]. Nat Rev Neurol, 2010,6(8):418-420. [9] Xiang GQ, Tang SS, Jiang LY, et al. PPARγ agonist pioglitazone improves scopolamine-induced memory impairment in mice[J].J Pharm Pharmacol,2012,64(4):589-596. [10] Kopelman MD, Corn TH. Cholinergic'blockade' as a model for cholinergic depletion.A comparison of thememory deficits with those of Alzheimer-type dementia and the alcoholic Korsakoff syndrome[J]. Brain Res,1988,111(Pt5): 1079-1110. |